Skip to main content
SpringerLink
Log in

Epstein-Barr Virus and Posttransplant Lymphoproliferative Disorders

  • Living reference work entry
  • First Online:
Emerging Transplant Infections

Abstract

Epstein-Barr virus (EBV) is an important potential cause of morbidity and mortality in children and adults undergoing solid organ (SOT) and hematopoietic stem cell transplantation (HSCT). The EBV virus is associated with a range of clinical symptoms and syndromes in both immunocompetent and immunocompromised patients based upon the virus’ ability to transform and immortalize B lymphocytes leading to viral-driven proliferation of infected B cells. In the immunocompetent host, this proliferation is primarily controlled by EBV-specific cytotoxic T lymphocytes (CTL). However, in the immunosuppressed SOT and HSCT recipient, impairment of the function of CTL can lead to unchecked proliferation and the development of EBV-associated posttransplant lymphoproliferative disorder (PTLD). In SOT recipients, the major risk factor for EBV-associated is being seronegative to the virus prior to and developing primary infection after the transplant, while in general SOT recipients who are EBV seropositive prior to transplant are at little risk for disease. For HSCT, the major risk factor relates to the EBV status and the potential T-cell depletion of the donor in an effort to minimize the risk of graft-versus-host disease (GVHD). In both SOT and HSCT, adverse outcomes relating to EBV infection led to efforts to optimize treatment and to develop preventive strategies to mitigate the impact of this pathogen. This chapter will review epidemiology, diagnosis, treatment, and prevention of EBV disease including PTLD in SOT and HSCT recipients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20): 2375–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: sixth European conference on infections in leukemia (ECIL-6) guidelines. Haematologica. 2016;101(7):803–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Allen UD, Preiksaitis JK, Practice ASTIDCo. Post-transplant lymphoproliferative disorders, EBV infection and disease in solid organ transplantation: guidelines from the American Society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33:e13652.

    Article  PubMed  Google Scholar 

  4. Fields BN, Knipe DM, Howley PM. Fields virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013.

    Google Scholar 

  5. Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013;13(Suppl 3):41–54; quiz.

    Article  CAS  PubMed  Google Scholar 

  6. Balfour HH Jr, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition. J Infect Dis. 2013;208(8):1286–93.

    Article  PubMed  Google Scholar 

  7. Kanakry JA, Hegde AM, Durand CM, Massie AB, Greer AE, Ambinder RF, et al. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood. 2016;127(16):2007–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Peters AC, Akinwumi MS, Cervera C, Mabilangan C, Ghosh S, Lai R, et al. The changing epidemiology of posttransplant lymphoproliferative disorder in adult solid organ transplant recipients over 30 years: a single-center experience. Transplantation. 2018;102(9):1553–62.

    Article  PubMed  Google Scholar 

  9. Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018;378(6):549–62.

    Article  CAS  PubMed  Google Scholar 

  10. Dharnidharka VR, Green M, Webber SA. Post-transplant lymphoproliferative disorders. Heidelberg: Springer; 2010. xii, 190p.

    Book  Google Scholar 

  11. Narkewicz MR, Green M, Dunn S, Millis M, McDiarmid S, Mazariegos G, et al. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience. Liver Transpl. 2013;19(7):730–40.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Green M, Michaels MG, Katz BZ, Burroughs M, Gerber D, Shneider BL, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant. 2006;6(8):1906–12.

    Article  CAS  PubMed  Google Scholar 

  13. Smith JM, Weaver T, Skeans MA, Horslen SP, Noreen SM, Snyder JJ, et al. OPTN/SRTR 2017 annual data report: intestine. Am J Transplant. 2019;19(Suppl 2):284–322.

    Article  PubMed  Google Scholar 

  14. Kandaswamy R, Stock PG, Gustafson SK, Skeans MA, Urban R, Fox A, et al. OPTN/SRTR 2017 annual data report: pancreas. Am J Transplant. 2019;19(Suppl 2):124–83.

    Article  PubMed  Google Scholar 

  15. Colvin M, Smith JM, Hadley N, Skeans MA, Uccellini K, Lehman R, et al. OPTN/SRTR 2017 annual data report: heart. Am J Transplant. 2019;19(Suppl 2):323–403.

    Article  PubMed  Google Scholar 

  16. Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Castro S, et al. OPTN/SRTR 2017 annual data report: kidney. Am J Transplant. 2019;19(Suppl 2):19–123.

    Article  PubMed  Google Scholar 

  17. Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, Noreen SM, et al. OPTN/SRTR 2017 annual data report: liver. Am J Transplant. 2019;19(Suppl 2):184–283.

    Article  PubMed  Google Scholar 

  18. Valapour M, Lehr CJ, Skeans MA, Smith JM, Uccellini K, Lehman R, et al. OPTN/SRTR 2017 annual data report: lung. Am J Transplant. 2019;19(Suppl 2):404–84.

    Article  PubMed  Google Scholar 

  19. Hertig A, Zuckermann A. Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: an update. Transpl Immunol. 2015;32(3):179–87.

    Article  CAS  PubMed  Google Scholar 

  20. Sang AX, McPherson MC, Ivison GT, Qu X, Rigdon J, Esquivel CO, et al. Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival. Am J Transplant. 2019;19(5):1305–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Bingler MA, Feingold B, Miller SA, Quivers E, Michaels MG, Green M, et al. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant. 2008;8(2):442–5.

    Article  CAS  PubMed  Google Scholar 

  22. Green M, Soltys K, Rowe DT, Webber SA, Mazareigos G. Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatr Transplant. 2009;13(3):319–23.

    Article  PubMed  Google Scholar 

  23. Lau AH, Soltys K, Sindhi RK, Bond G, Mazariegos GV, Green M. Chronic high Epstein-Barr viral load carriage in pediatric small bowel transplant recipients. Pediatr Transplant. 2010;14(4):549–53.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Yamada M, Nguyen C, Fadakar P, Ganoza A, Humar A, Shapiro R, et al. Epidemiology and outcome of chronic high Epstein-Barr viral load carriage in pediatric kidney transplant recipients. Pediatr Transplant. 2018;22:e13147.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Chinnock R, Webber SA, Dipchand AI, Brown RN, George JF, Pediatric Heart Transplant Study. A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients. Am J Transplant. 2012;12(11):3061–8.

    Article  CAS  PubMed  Google Scholar 

  26. Rouce RH, Louis CU, Heslop HE. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol. 2014;21(6):476–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113(20):4992–5001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Bowden RA, Ljungman P, Snydman DR. Transplant infections. 3rd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2010. xii, 788p

    Google Scholar 

  29. Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, et al. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol. 2017;35(5):536–43.

    Article  CAS  PubMed  Google Scholar 

  30. Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis. 2009;11(5):383–92.

    Article  CAS  PubMed  Google Scholar 

  31. Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, Roberts S, Tyrrell DL. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis. 1992;166(5):986–94.

    Article  CAS  PubMed  Google Scholar 

  32. Rowe DT, Qu L, Reyes J, Jabbour N, Yunis E, Putnam P, et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol. 1997;35(6):1612–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Nowalk A, Green M. Epstein-Barr virus. Microbiol Spectr. 2016;4(3) https://doi.org/10.1128/microbiolspec.DMIH2-0011-2015.

  34. Preiksaitis JK, Pang XL, Fox JD, Fenton JM, Caliendo AM, Miller GG, et al. Interlaboratory comparison of Epstein-Barr virus viral load assays. Am J Transplant. 2009;9(2):269–79.

    Article  CAS  PubMed  Google Scholar 

  35. Hayden RT, Sun Y, Tang L, Procop GW, Hillyard DR, Pinsky BA, et al. Progress in quantitative viral load testing: variability and impact of the WHO quantitative international standards. J Clin Microbiol. 2017;55(2):423–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Fryer JF, Heath AB, Wilkinson DE, Minor PD. The Collaborative study Group. Collaborative study to evaluate the proposed 1st WHO international standardfor EpsteineBarr virus (EBV) for nucleic acid amplification (NAT)-based assays. WHO ECBS Report. Geneva, Switzerland: World Health Organization 2011; WHO/BS/2011.2172, http://whqlibdoc.who.int/hq/2011/WHO_BS_2011.2172_eng.pdf

  37. Smets F, Latinne D, Bazin H, Reding R, Otte JB, Buts JP, et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation. 2002;73(10):1603–10.

    Article  PubMed  Google Scholar 

  38. Martinez OM, Krams SM. The immune response to Epstein Barr virus and implications for posttransplant lymphoproliferative disorder. Transplantation. 2017;101(9):2009–16.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Sebelin-Wulf K, Nguyen TD, Oertel S, Papp-Vary M, Trappe RU, Schulzki A, et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol. 2007;17(3):203–10.

    Article  CAS  PubMed  Google Scholar 

  40. Yamada M, Nowalk AJ. Two sides of the Epstein-Barr virus (EBV) coin: Long-term control of EBV after liver transplantation? Pediatr Transplant. 2017;21(5):e12943.

    Article  Google Scholar 

  41. Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers. 2016;2:15088.

    Article  PubMed  Google Scholar 

  42. Panagiotidis E, Quigley AM, Pencharz D, Ardeshna K, Syed R, Sajjan R, et al. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder. Leuk Lymphoma. 2014;55(3):515–9.

    Article  PubMed  Google Scholar 

  43. Hayashi RJ, Kraus MD, Patel AL, Canter C, Cohen AH, Hmiel P, et al. Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol. 2001;23(1):14–8.

    Article  CAS  PubMed  Google Scholar 

  44. Webber SA, Naftel DC, Fricker FJ, Olesnevich P, Blume ED, Addonizio L, et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet. 2006;367(9506):233–9.

    Article  PubMed  Google Scholar 

  45. Messahel B, Taj MM, Hobson R, Hadzic N, Ramsay A, Hann I, et al. Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: a United Kingdom Children’s Cancer Study Group (UKCCSG) retrospective review. Leuk Lymphoma. 2006;47(12):2584–9.

    Article  CAS  PubMed  Google Scholar 

  46. Choquet S, Trappe R, Leblond V, Jager U, Davi F, Oertel S. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica. 2007;92(2):273–4.

    Article  PubMed  Google Scholar 

  47. Gonzalez-Barca E, Domingo-Domenech E, Capote FJ, Gomez-Codina J, Salar A, Bailen A, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica. 2007;92(11):1489–94.

    Article  CAS  PubMed  Google Scholar 

  48. Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol. 2005;23(27):6481–8.

    Article  CAS  PubMed  Google Scholar 

  49. Gross TG, Orjuela MA, Perkins SL, Park JR, Lynch JC, Cairo MS, et al. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children’s Oncology Group Report. Am J Transplant. 2012;12(11):3069–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Cavaliere R, Petroni G, Lopes MB, Schiff D, International Primary Central Nervous System Lymphoma Collaborative Group. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer. 2010;116(4):863–70.

    Article  PubMed  Google Scholar 

  51. Evens AM, Choquet S, Kroll-Desrosiers AR, Jagadeesh D, Smith SM, Morschhauser F, et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am J Transplant. 2013;13(6):1512–22.

    Article  CAS  PubMed  Google Scholar 

  52. Perrine SP, Hermine O, Small T, Suarez F, O’Reilly R, Boulad F, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007;109(6):2571–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Shirley CM, Chen J, Shamay M, Li H, Zahnow CA, Hayward SD, et al. Bortezomib induction of C/EBPbeta mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. Blood. 2011;117(23):6297–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Gottschalk S, Rooney CM. Adoptive T-cell immunotherapy. Curr Top Microbiol Immunol. 2015;391:427–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110(4):1123–31.

    Article  CAS  PubMed  Google Scholar 

  56. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Abedi MR, Linde A, Christensson B, Mackett M, Hammarstrom L, Smith CI. Preventive effect of IgG from EBV-seropositive donors on the development of human lympho-proliferative disease in SCID mice. Int J Cancer. 1997;71(4):624–9.

    Article  CAS  PubMed  Google Scholar 

  58. Opelz G, Daniel V, Naujokat C, Fickenscher H, Dohler B. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol. 2007;8(3):212–8.

    Article  CAS  PubMed  Google Scholar 

  59. Humar A, Hebert D, Davies HD, Humar A, Stephens D, O’Doherty B, et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation. 2006;81(6):856–61.

    Article  CAS  PubMed  Google Scholar 

  60. Schachtner T, Reinke P. Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study. Transpl Infect Dis. 2016;18(6):881–8.

    Article  CAS  PubMed  Google Scholar 

  61. Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant. 2002;21(5):547–54.

    Article  PubMed  Google Scholar 

  62. Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation. 1997;64(6):848–52.

    Article  CAS  PubMed  Google Scholar 

  63. Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin Transpl. 1995;9(1):53–9.

    CAS  Google Scholar 

  64. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant. 2005;5(12):2894–900.

    Article  CAS  PubMed  Google Scholar 

  65. Green M, Kaufmann M, Wilson J, Reyes J. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis. 1997;25(6): 1344–9.

    Article  CAS  PubMed  Google Scholar 

  66. Hocker B, Fickenscher H, Delecluse HJ, Bohm S, Kusters U, Schnitzler P, et al. Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study. Clin Infect Dis. 2013;56(1):84–92.

    Article  PubMed  Google Scholar 

  67. AlDabbagh MA, Gitman MR, Kumar D, Humar A, Rotstein C, Husain S. The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review. Am J Transplant. 2017;17(3):770–81.

    Article  CAS  PubMed  Google Scholar 

  68. Hocker B, Bohm S, Fickenscher H, Kusters U, Schnitzler P, Pohl M, et al. (Val-)ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation. Transpl Int. 2012;25(7):723–31.

    Article  PubMed  CAS  Google Scholar 

  69. McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation. 1998;66(12):1604–11.

    Article  CAS  PubMed  Google Scholar 

  70. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005;5(9):2222–8.

    Article  PubMed  Google Scholar 

  71. Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients. J Pediatr Gastroenterol Nutr. 2004;38(2):198–203.

    Article  CAS  PubMed  Google Scholar 

  72. Martin SI, Dodson B, Wheeler C, Davis J, Pesavento T, Bumgardner GL. Monitoring infection with Epstein-Barr virus among seromismatch adult renal transplant recipients. Am J Transplant. 2011;11(5):1058–63.

    Article  CAS  PubMed  Google Scholar 

  73. van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99(12):4364–9.

    Article  PubMed  Google Scholar 

  74. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92(5):1549–55.

    Article  CAS  PubMed  Google Scholar 

  75. Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006;108(9):2942–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division for Advanced Medicine for Virus Infections, National Center Child Health and Development, Tokyo, Japan

    Masaki Yamada

  2. Department of Pediatrics, University of Pittsburgh School of Medicine and UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

    Masaki Yamada, Andrew Nowalk & Michael Green

  3. Department of Surgery, University of Pittsburgh School of Medicine and UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

    Michael Green

Authors
  1. Masaki Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Nowalk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Green
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Green .

Editor information

Editors and Affiliations

  1. Miller School of Medicine, University of Miami, Miami, FL, USA

    Michele I. Morris

  2. Massachusetts General Hospital, Harvard University, Boston, MA, USA

    Camille Nelson Kotton

  3. Duke University, Durham, NC, USA

    Camille Wolfe

Section Editor information

  1. Duke University, Durham, NC, USA

    Cameron R. Wolfe

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Yamada, M., Nowalk, A., Green, M. (2020). Epstein-Barr Virus and Posttransplant Lymphoproliferative Disorders. In: Morris, M., Kotton, C., Wolfe, C. (eds) Emerging Transplant Infections. Springer, Cham. https://doi.org/10.1007/978-3-030-01751-4_27-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-01751-4_27-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-01751-4

  • Online ISBN: 978-3-030-01751-4

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation